AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2020. The put-call ratio across all filers is 0.75 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $188,000 | +34.3% | 20,781 | -1.1% | 0.00% | – |
| Q4 2020 | $140,000 | +28.4% | 21,019 | -2.7% | 0.00% | – |
| Q3 2020 | $109,000 | -37.7% | 21,600 | -0.3% | 0.00% | – |
| Q2 2020 | $175,000 | +48.3% | 21,663 | +45.2% | 0.00% | – |
| Q1 2020 | $118,000 | 0.0% | 14,919 | -4.4% | 0.00% | – |
| Q4 2019 | $118,000 | +81.5% | 15,610 | -0.3% | 0.00% | – |
| Q3 2019 | $65,000 | +44.4% | 15,660 | +0.1% | 0.00% | – |
| Q2 2019 | $45,000 | +87.5% | 15,646 | -7.0% | 0.00% | – |
| Q1 2019 | $24,000 | -45.5% | 16,824 | -2.1% | 0.00% | – |
| Q4 2018 | $44,000 | -42.9% | 17,184 | -2.0% | 0.00% | – |
| Q3 2018 | $77,000 | -18.9% | 17,536 | +13.3% | 0.00% | – |
| Q2 2018 | $95,000 | -5.9% | 15,473 | +11.5% | 0.00% | – |
| Q1 2018 | $101,000 | -12.9% | 13,871 | -2.1% | 0.00% | – |
| Q4 2017 | $116,000 | -24.7% | 14,172 | -3.6% | 0.00% | – |
| Q3 2017 | $154,000 | -7.2% | 14,706 | -2.3% | 0.00% | – |
| Q2 2017 | $166,000 | +7.1% | 15,048 | -6.0% | 0.00% | – |
| Q1 2017 | $155,000 | – | 16,009 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |